findmyKOL
Clinical trialNCT03639948UnknownPhase 2Interventional

Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer

SponsorUniversity of Kansas Medical CenterEnrollment120Triple-negative Breast Cancer
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • the University of Kansas Cancer Center (kucc)

    Fairway, Kansas, United States

  • the University of Kansas Cancer Center, West Clinic

    Kansas City, Kansas, United States

  • the University of Kansas Cancer Center, Westwood Campus

    Kansas City, Kansas, United States

  • University of Kansas Cancer Center

    Kansas City, Kansas, United States

  • the University of Kansas Cancer Center, Overland Park Clinic

    Overland Park, Kansas, United States

  • the University of Kansas Cancer Center, North Clinic

    Kansas City, Missouri, United States

  • the University of Kansas Cancer Center, Lee'S Summit Clinic

    Lee's Summit, Missouri, United States

  • the University of Kansas Medical Center

    North Kansas City, Missouri, United States

  • Texas Oncology- Baylor

    Dallas, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
4 Sept 2018
Primary completion
27 Jan 2022
Completion
30 Nov 2024
Last update posted
11 Apr 2024
Registered enrollment
120
Registry id
NCT03639948
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.